

Status: Currently Official on 16-Feb-2025

Official Date: Official as of 01-May-2018

Document Type: USP Monographs

DocId: GUID-F98CF85B-4622-4552-9F63-E932B18FF65B\_3\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M60049\\_03\\_01](https://doi.org/10.31003/USPNF_M60049_03_01)

DOI Ref: f86ej

© 2025 USPC

Do not distribute

## Oxytetracycline for Injection

» Oxytetracycline for Injection contains an amount of Oxytetracycline Hydrochloride equivalent to not less than 90.0 percent and not more than 115.0 percent of the labeled amount of oxytetracycline ( $C_{22}H_{24}N_2O_9$ ).

**Packaging and storage**—Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging](#), [Packaging for constitution](#), protected from light.

**USP REFERENCE STANDARDS (11)**—

[USP Oxytetracycline RS](#)

**Constituted solution**—At the time of use, it meets the requirements for [Injections and Implanted Drug Products \(1\)](#), [Specific Tests](#), [Completeness and clarity of solutions](#).

**BACTERIAL ENDOTOXINS TEST (85)**—It contains not more than 0.4 USP Endotoxin Unit per mg of oxytetracycline.

**STERILITY TESTS (71)**—It meets the requirements when tested as directed for [Membrane Filtration](#) under [Test for Sterility of the Product to be Examined](#), *Fluid D* being used instead of *Fluid A*.

**pH (791)**: between 1.8 and 2.8, in a solution containing 25 mg per mL.

**Loss on drying (731)**—Dry about 100 mg, accurately weighed, in a capillary-stoppered bottle in vacuum at a pressure not exceeding 5 mm of mercury at 60° for 3 hours: it loses not more than 3.0% of its weight.

**PARTICULATE MATTER IN INJECTIONS (788)**: meets the requirements for small-volume injections.

**Other requirements**—It responds to [Identification](#) test *B* under [Oxytetracycline Hydrochloride](#). It also meets the requirements for [Uniformity of Dosage Units \(905\)](#) and [Labeling \(7\)](#), [Labels and Labeling for Injectable Products](#).

**Assay**—

*Tetrabutylammonium hydrogen sulfate solution, Eddate disodium solution, pH 7.5 Phosphate buffer, Mobile phase, Standard preparation, System suitability solution, and Chromatographic system*—Proceed as directed in the [Assay](#) under [Oxytetracycline](#).

*Assay preparation 1* (where it is represented as being in a single-dose container)—Constitute Oxytetracycline for Injection in a volume of water, accurately measured, corresponding to the volume of solvent specified in the labeling. Withdraw all of the withdrawable contents, using a suitable hypodermic needle and syringe, and dilute quantitatively with 0.01 N hydrochloric acid to obtain a solution having a concentration of about 0.2 mg of oxytetracycline per mL.

*Assay preparation 2* (where the label states the quantity of oxytetracycline in a given volume of constituted solution)—Constitute Oxytetracycline for Injection in a volume of water, accurately measured, corresponding to the volume of solvent specified in the labeling.

Dilute an accurately measured volume of the constituted solution quantitatively with 0.01 N hydrochloric acid to obtain a solution having a concentration of about 0.2 mg of oxytetracycline per mL.

**Procedure**—Proceed as directed for [Procedure](#) in the [Assay](#) under [Oxytetracycline](#). Calculate the quantity, in mg, of oxytetracycline

( $C_{22}H_{24}N_2O_9$ ) withdrawn from the container or in the portion of constituted solution taken by the formula:

$$(L/D)(CP)(r_u/r_s)$$

in which *L* is the labeled quantity, in mg, of oxytetracycline ( $C_{22}H_{24}N_2O_9$ ) in the container or in the portion of constituted solution taken; *D* is the concentration, in mg per mL, of oxytetracycline in *Assay preparation 1* or in *Assay preparation 2*, based on the labeled quantity in the container or in the portion of constituted solution taken, respectively, and the extent of dilution; and the other terms are as defined therein.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
OXYTETRACYCLINE FOR INJECTION	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1

Topic/Question	Contact	Expert Committee
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM12020 Small Molecules 1

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

**Current DocID:** [GUID-F98CF85B-4622-4552-9F63-E932B18FF65B\\_3\\_en-US](#)

**Previous DocID:** [GUID-F98CF85B-4622-4552-9F63-E932B18FF65B\\_1\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M60049\\_03\\_01](https://doi.org/10.31003/USPNF_M60049_03_01)

**DOI ref:** [f86ej](#)

OFFICIAL